Tag: drug-coated balloons

VIVA 2019: SELUTION sirolimus DCB safe and effective through two years

The SELUTION SFA trial met its primary endpoint and demonstrated an late lumen loss of 0.19mm. Furthermore, excellent freedom from clinically driven TLR was...

Philips receives FDA approval for low-dose drug-coated balloons

Philips has received US Food and Drug Administration (FDA) approval for two Stellarex 0.035” low-dose (200mm and 150mm) drug-coated balloons for the treatment of...

A panel of experts comments on IN.PACT AV ACCESS data

NOTE: This video is ONLY available to watch in selected countries and geographies   Jos van den Berg (Lugano, Switzerland) speaks to Andrew Holden (Auckland, New...
MDA

MHRA issues medical device alert for paclitaxel use in the UK

Do not use paclitaxel drug-coated balloons (DCBs) or drug-eluting stents (DESs) in the routine treatment of patients with intermittent claudication until further notice, a...
medtronic

Meta-analysis finds a higher risk of death in the long term...

New data, just published in the Journal of the American Heart Association (JAHA), suggest that there is an increased risk of death at two...
paclitaxel

Without additional long-term and patient-level data, Katsanos et al’s conclusion is...

By Thomas Zeller The Katsanos et al meta-analysis reports an increased risk of mortality beyond one year across randomised studies of paclitaxel-coated balloons (DCB) and...